Arcturus Therapeutics Ltd (ARCT) Receives Average Recommendation of “Buy” from Analysts

Arcturus Therapeutics Ltd (NASDAQ:ARCT) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the stock, reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.83.

A number of research analysts have recently commented on ARCT shares. ValuEngine downgraded Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Zacks Investment Research upgraded Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Thursday, January 3rd. Laidlaw started coverage on Arcturus Therapeutics in a research note on Tuesday, February 19th. They set a “buy” rating on the stock. Roth Capital restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, February 20th. Finally, Chardan Capital restated a “buy” rating and set a $18.00 price target on shares of Arcturus Therapeutics in a research note on Tuesday, March 19th.

Shares of ARCT traded down $0.36 during mid-day trading on Wednesday, reaching $7.44. The company’s stock had a trading volume of 20,900 shares, compared to its average volume of 51,412. Arcturus Therapeutics has a 12-month low of $4.11 and a 12-month high of $10.00. The company has a market cap of $83.93 million, a P/E ratio of -3.44 and a beta of 2.17. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.33 and a current ratio of 3.33.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.41. The business had revenue of $7.58 million during the quarter, compared to analysts’ expectations of $3.59 million. As a group, analysts predict that Arcturus Therapeutics will post -2.11 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Arcturus Therapeutics stock. JPMorgan Chase & Co. increased its position in shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) by 91.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,744 shares of the biotechnology company’s stock after buying an additional 8,008 shares during the quarter. JPMorgan Chase & Co. owned about 0.16% of Arcturus Therapeutics worth $148,000 as of its most recent SEC filing. 10.86% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Read More: What are the benefits of a balanced fund?

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.